Prescribed Medication for Acute Treatment for Migraine Market By Drug Type (Abortive and Prophylactic), By Route of Administration (Oral, Injectables and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)  and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Prescribed Medication For Acute Treatment For Migraine Market size estimated to be valued at USD 2,587.9 million in 2021 and is poised to grow at a significant CAGR of 13.7% over 2022-2028. The market for prescribed medications for acute treatment of migraine is expected to offer lucrative opportunities for the market players due to the launch of novel molecules in the U.S. market. The companies have focused on novel therapeutics, an alternative to the triptan class of drugs due to the adverse effects like cardiovascular disorders, chest pressure, and others. Novel treatment options and increased prevalence of migraine are expected to drive the market. Increased awareness initiatives, the availability of research funds from private and public bodies, a development in the reimbursement scenario for associated medications, and increasing awareness about the effectiveness of such medicines are among the significant factors fuelling the market's growth. Furthermore, rising pharmaceutical R&D operating costs and rising healthcare spending are expected to drive the global prescribed medications for acute migraine treatment market growth rate during the forecast period. In the prescribed medications for acute treatment of migraine market, abortive prescribed medications for acute treatment of migraine accounted for a larger revenue share in 2021 and are projected to grow with a CAGR of 13.9% from 2022-2028 to reach US$ 1,653.7 Mn by 2028. However, the market for prophylactic drugs is anticipated to grow with a significant CAGR over the forecast years in prescribed medications for acute treatment of migraine.

Recent Market Developments:

In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. In January 2022, BioDelivery Sciences launched a new drug Elyxyb (celecoxib oral solution), a fast-acting liquid. It is one of the first Food and Drug Administration-approved ready-to-use oral solutions for adults in the acute treatment of migraine, with or without aura.

Global Prescribed Medication For Acute Treatment For Migrane Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Prescribed Medication for Acute Treatment for Migraine Market

The increasing awareness of novel drug classes and the rising incidence of migraine problems worldwide drive the target market's growth. Additionally, factors such as increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients associated with the prevention and treatment of migraine further increase the demand levels for the global prescribed medications for acute treatment of migraine market. The increasing precedence of other therapies and side effects associated with migraine drugs limit the growth of the prescribed medications for acute migraine treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

Global Prescribed Medication For Acute Treatment For Migrane Market Segmentation

Drug Type
  • Abortive
  • Prophylactic
  • Oral
  • Injectables
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
North America
  • US
  • Canada
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Poland
  • Rest of Europe
  • Japan
  • China
  • India
  • AU & NZ
  • Rest of APAC
Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Rest of Latin America
Middle East & Africa
  • GCC
  • Israel
  • SA
  • Rest of MEA

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • AstraZeneca Plc.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Endo Pharmaceuticals Inc.
  • Avanir Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Biohaven Pharmaceutical Holding Co., Ltd